KKKoji Kato

Koji Kato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Koji Kato has a total of 264 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Second allogeneic haematopoietic stem cell transplantation for non‐malignant diseases

    by Maiko Shimomura, Koji Kawaguchi, Shohei Yamamoto, Michiko Kajiwara, Takashi Koike, Masataka Ishimura, Nao Yoshida, Maho Sato, Katsuyoshi Koh, Keiko Okada, et al.

    Summary: We retrospectively analysed clinical outcomes of 152 patients with non‐malignant diseases (NMDs) who underwent a second allogeneic haematopoietic stem cell transplantation (HSCT), using a composite end‐point, graft‐versus‐host disease (GVHD)‐free, relapse (i.e. graft failure)‐free and subsequent transplant‐free survival (GRSFS), to assess major failure events. The 5‐year overall survival (OS) and GRSFS rates were 67.0% and 52.1%, respectively. Graft failure (GF) was the most frequent GRSFS failure event, occurring in 24.5% of patients. In multivariate analysis, use of a human leucocyte antigen 0–1 antigen mismatch unrelated bone marrow (BM)/peripheral blood stem cell (PBSC) donor, unrelated cord blood (CB) donor and no donor change were associated with lower incidence of engraftment ( p < 0.01). In addition to conditioning and human leucocyte antigen (HLA) compatibility in second HSCT, disease group was identified as an independent risk factor for GRSFS. Specifically, patients with haemophagocytic lymphohistiocytosis had the poorest outcome ( p = 0.04), while those with inherited metabolic diseases (IMDs) tended towards more favourable outcome ( p = 0.06). Among the 51 deaths, 44 (86.6%) were attributed to causes other than the original disease, with variation across disease groups. GRSFS may be a useful metric to quantify the clinical impact of major failure events and to inform strategies for second HSCT in NMDs.

  • Differential Impact of Graft-Versus-Host Disease Prophylaxis on Cytomegalovirus Infection and Survival Outcomes after Cord Blood Transplantation in the Era of Letermovir

    by Shunto Kawamura, Yu Akahoshi, Hideki Nakasone, Naoyuki Uchida, Makoto Onizuka, Keisuke Kataoka, Koji Kato, Toshiro Kawakita, Mamiko Sakata-Yanagimoto, Masashi Sawa, et al.

  • Donor age as a dual‐risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation

    by Satoshi Nishiwaki, Yoshiko Atsuta, Ryu Yanagisawa, Hideki Nakasone, Takashi Nagayama, Fumiya Wada, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, et al.

    Summary: Donor selection in allogeneic haematopoietic stem cell transplantation (allo‐HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual—association donor factors (DADFs)—donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival—using umbilical cord blood (UCB) as a donor‐safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013–2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)‐adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post‐transplant cyclophosphamide (OD‐PTCy‐Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW‐adjusted analyses, allo‐HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse‐free survival (RFS) compared with UCB. In PSM analyses of elderly high‐risk recipients, OD‐PTCy‐Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high‐risk settings.

  • Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders

    by Koji Kawaguchi, Satoshi Miyamoto, Nao Yoshida, Shohei Yamamoto, Takashi Koike, Satoshi Okada, Michiko Kajiwara, Yoshiyuki Takahashi, Masataka Ishimura, Hirotoshi Sakaguchi, et al.

    Summary: In allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for genetic disorders (GDs), predicting outcomes using the currently used myeloablative/reduced‐intensity conditioning classification is challenging. We examined the utility of the transplant conditioning intensity (TCI) score in allo‐HSCT for GDs. We retrospectively analysed 1077 patients who underwent first allo‐HSCT for GDs between 1987 and 2018. While no significant difference was observed in 3‐year non‐relapse mortality (NRM) between the myeloablative and reduced‐intensity conditioning group, 3‐year NRM in the TCI score ≥4.0 (TCI‐high) group (17.3%) was higher than that in the TCI score 0.5–3.5 (TCI‐low/intermediate) group (11.6%, p = 0.013). Multivariate analysis identified a high TCI score as a significant factor for NRM (HR 1.56, p = 0.011). Infection‐related mortalities were more prevalent in the TCI‐high group (7.9%) compared with the TCI‐low/intermediate group (3.2%). In contrast, patients in the TCI‐high group achieved a significantly higher rate of complete donor chimerism (71.7%) than those in the TCI‐low/intermediate group (62.2%, p = 0.022). TCI score is a valuable tool for predicting outcomes after allo‐HSCT for GDs as well as for guiding the selection of conditioning regimens tailored to the unique characteristics of GDs.


  • Open Access

    Donor type/graft source selection strategies based on disease status for paediatric acute myeloid leukemia transplantation

    by Yoshiko Hashii, Hiroyuki Ishida, Takashi Taga, Daisuke Tomizawa, Satoshi Hattori, Maho Sato, Katsuyoshi Koh, Nao Yoshida, Utako Oba, Maiko Noguchi, et al.

    In the absence of a human leukocyte antigen-matched sibling donor for paediatric patients with acute myeloid leukemia (AML) who underwent the first allogeneic hematopoietic cell transplantation (allo-HCT), the optimal donor type/graft source remain undetermined among donor types—haploidentical related donor (HRD) and matched unrelated donor (MUD)—as well as graft source—umbilical cord blood (UCB). This study aimed to determine the optimal donor type/graft source. The Japanese database on 441 recipients (median age, 6.0 years, range [0.0–15.0]) for HRD (n = 71), MUD (n = 111), and UCB (n = 259) was analyzed retrospectively. Regarding recipients in remission [complete remission (CR) 1 or CR2 at allo-HCT, n = 271], the rate of a composite endpoint consisting of extensive chronic graft-versus-host disease (cGVHD)- and leukemia-free survival (LFS)—extensive cGVHD-LFS—was not statistically significant among UCB, MUD, and HRD recipients. Regarding recipients not in remission (n =170), extensive cGVHD-LFS was significantly higher for MUD recipients than for UCB ( p = 0.007) and HRD ( p = 0.015) recipients. HRD, MUD, and UCB were optimal for recipients in remission, while MUD was optimal for recipients not in remission. Namely, the donor type/graft source needs to be selected based on disease status at HCT.

  • Open Access

    A Retrospective Study of Pediatric Patients With Low- or Intermediate-Risk Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation for the AML-05 Study Conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group

    by Yoshiko Hashii, Koji Kawaguchi, Hiroyuki Kurakami, Katsutsugu Umeda, Daiichiro Hasegawa, Tomohiko Taki, Nobuyuki Hyakuna, Hiroyuki Ishida, Yoshiyuki Takahashi, Masayuki Nagasawa, et al.


  • Open Access

    Machine Learning Prediction Model for Neutrophil Recovery after Unrelated Cord Blood Transplantation

    by Yachiyo Kuwatsuka, Rika Kasajima, Rui Yamaguchi, Naoyuki Uchida, Takaaki Konuma, Masatsugu Tanaka, Naoki Shingai, Shigesaburo Miyakoshi, Yasuji Kozai, Yasufumi Uehara, et al.


  • Clinical characteristics and risk factors of pneumococcal diseases in recipients of allogeneic hematopoietic stem cell transplants in the late phase: A retrospective registry study

    by Keiji Okinaka, Yoshitaka Inoue, Naoyuki Uchida, Takashi Toya, Hiroyasu Ogawa, Yukiyasu Ozawa, Tetsuya Eto, Takehiko Mori, Junichi Sugita, Tadakazu Kondo, et al.


  • Prognostic value of pre-transplantation total metabolic tumor volume on 18fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography in relapsed and refractory aggressive lymphoma

    by Takeshi Sugio, Shingo Baba, Yasuo Mori, Goichi Yoshimoto, Kenjiro Kamesaki, Shuichiro Takashima, Shingo Urata, Takahiro Shima, Kohta Miyawaki, Yoshikane Kikushige, et al.

    Relapsed and refractory aggressive lymphoma have a poor prognosis. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is effective in chemosensitive patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is among the few options for non-chemosensitive patients. 18Fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography (18FDG-PET/CT) is the standard tool for evaluating response to chemotherapy and residual tumor volume. However, accurate assessment of residual tumor volume is not currently being achieved in clinical practice, and its value in prognostic and therapeutic stratification remains unclear. To answer this question, we investigated the efficacy of quantitative indicators, including total metabolic tumor volume (TMTV), in predicting prognosis after auto-HSCT and allo-HSCT. We retrospectively analyzed 39 patients who received auto-HSCT and 28 who received allo-HSCT. In the auto-HSCT group, patients with a higher TMTV had a poor prognosis due to greater risk of relapse. In the allo-HSCT group, patients with a higher TMTV had a lower progression-free survival rate and a significantly higher relapse rate. Neither Deauville score nor other clinical parameters were associated with prognosis in either group. Therefore, pre-transplant TMTV on PET is effective for prognostic prediction and therapeutic decision-making for relapsed or refractory aggressive lymphoma.


  • Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan

    by Koji Kato, Hiromasa Yabe, Nobuyuki Shimozawa, Souichi Adachi, Mineo Kurokawa, Yoshiko Hashii, Atsushi Sato, Nao Yoshida, Makiko Kaga, Osamu Onodera, et al.

    Background: Adrenoleukodystrophy (ALD) is an X‐linked recessive disorder and 30–40% of patients develop progressive cerebral neurodegeneration. For symptomatic ALD patients, allogeneic stem cell transplantation (SCT) is considered the standard treatment modality to stabilize or prevent the progression of neurological symptoms.Methods: We retrospectively analyzed the transplant outcomes of 99 pediatric patients with cerebral ALD in Japan. The conditioning regimens included Regimen A: fludarabine/melphalan/low‐dose total body irradiation (TBI) with brain sparing (n = 39), Regimen B; busulfan/cyclophosphamide ± others (n = 23), Regimen C: melphalan/total lymphoid irradiation/thoracoabdominal irradiation ± anti‐T lymphocyte globulin ± fludarabine (n = 27), and Regimen D: others (n = 10).Results: The 5‐year overall survival (OS) and event‐free survival (EFS) of all patients were 90.0% and 72.9%, respectively. The 5‐year OS was 100.0% for Regimen A, 91.1% for Regimen B, 84.4% for Regimen C, and 67.5% for Regimen D (p = 0.028). The 5‐year EFS was 78.3% for Regimen A, 78.0% for Regimen B, 70.4% for Regimen C, and 48.0% for Regimen D (p = 0.304). The OS marginally improved after 2007 compared with before 2006 (95.3% vs. 85.2%, p = 0.066), due to the improvement of cord blood transplantation (CBT) outcomes after 2007 compared with before 2006 (96.6% vs. 68.4%, p = 0.005). On magnetic resonance imaging of the brain, a reduced Loes score after SCT was only observed in one of the 15 bone marrow transplantation (BMT) patients, but in 5 of the 15 CBT patients (p = 0.173).Conclusions: Our study revealed that a reduced conditioning regimen with fludarabine/melphalan/low‐dose TBI provides better outcomes, and the results of CBT significantly improved after 2007.